Companies › Consun Pharmaceutical Group
2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology, Genitourinary; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SK-09 | – | Phase 1 | FSGS | Apr 2027 |
| SK-08 | – | Phase 1 | Chronic Kidney Disease(CKD) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07021157 | SK-08 | Phase 1 | Chronic Kidney Disease(CKD) | Genitourinary | Aug 2025 |
| NCT07267026 | SK-09 | Phase 1 | FSGS | Ophthalmology | Apr 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.